The DRAGEN Bio-IT Platform has been integrated into HudsonAlpha Institute for Biotechnology’s next-generation sequencing workflow, increasing the throughput of the sequencing facility and eliminating the need for expensive servers. The DRAGEN Germline Pipeline includes optimized algorithms for BCL conversion, compression, mapping, alignment, sorting, duplicate marking, haplotype variant calling, and joint genotyping. The reconfigurable processor can be loaded with pipelines for RNAseq, cancer variant detection, methylome, and microbiome.
As part of the DRAGEN integration, HudsonAlpha developed a front-end management system to enable robust and automated transfer of data from a collection of sequencers to the DRAGEN processor, and automated reporting of results after each analysis. DRAGEN is available in a pre-configured server that facilitates the seamless integration of secondary analysis into next-generation sequencing workflows.
DRAGEN is currently used in Dr. Levy’s Genomic Services Laboratory, as well as in its newly established Clinical Services Laboratory, which performs whole genome sequencing for patients with medical conditions. The processor also is used in HudsonAlpha’s Clinical Sequencing Exploratory Research (CSER) consortium project, initiated by the National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), which seeks to evaluate the benefits of genome and exome sequencing in clinical settings.